![](/img/cover-not-exists.png)
Cost-effectiveness analysis of adding ramucirumab to the first-line erlotinib treatment for untreated EGFR-mutated metastatic non-small cell lung cancer in China
Liu, Qiao, Luo, Xia, Peng, Liubao, Yi, Lidan, Wan, Xiaomin, Zeng, Xiaohui, Tan, ChongqingVolume:
10
Journal:
BMJ Open
DOI:
10.1136/bmjopen-2020-040691
Date:
November, 2020
File:
PDF, 1.21 MB
2020